Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a compassionate use study. In addition to providing compassionate use access to
mifepristone, objectives of the study will be to evaluate the safety and utility of
mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when
given on a compassionate use basis. The study will only enroll subjects whose physicians have
determined that medical treatment is needed to control the symptoms or signs of
hypercortisolemia.